Researchers at McMaster University and the Massachusetts Institute of Technology have used artificial intelligence to identify a new antibiotic, named enterololin, that targets harmful gut bacteria while leaving beneficial microbes untouched. The finding, published in Nature Microbiology, could offer a more precise alternative to broad-spectrum antibiotics for people with gastrointestinal conditions, including those living with Crohn’s disease.
Background
Conventional antibiotics are typically “broad spectrum”, meaning they eliminate harmful and beneficial bacteria alike. For people with Crohn’s disease, this is a particular concern, as it can leave the gut vulnerable to opportunistic pathogens such as E. coli, which are already more prevalent in some patients with inflammatory bowel disease (IBD). Developing narrow-spectrum drugs that target specific bacterial families has long been a goal in gastroenterology, but the laboratory process of screening compounds and understanding how they work has historically taken years. Artificial intelligence is increasingly being explored as a way to shorten this timeline.
Key Findings
According to the study authors, the AI model was used to predict the mechanism of action of new chemical compounds, a process that would traditionally take years of laboratory work, in a matter of seconds. Using this approach, the team identified enterololin, a compound that specifically targets bacteria within the Enterobacteriaceae family, which includes strains such as E. coli that can proliferate in an inflamed or disrupted gut. Unlike broad-spectrum antibiotics, enterololin was shown to leave the wider protective gut microbiome intact. The researchers describe this as evidence that AI-driven models can substantially accelerate the discovery of narrow-spectrum treatments, a task that has proven difficult using traditional drug discovery methods alone.
Clinical Relevance
For clinicians managing IBD, the prospect of narrow-spectrum antibiotics is notable because recurring gut infections and microbial imbalance are common complications, particularly in Crohn’s disease. A treatment that suppresses harmful bacteria without further destabilising the microbiome could, in principle, reduce the knock-on effects that broad-spectrum antibiotics can have on gut health. The researchers frame this as an early but meaningful step towards more targeted therapies, rather than an immediate change to clinical practice. Further research and clinical trials would be needed before enterololin, or similar AI-identified compounds, could be considered for patient use.
Reference
McMaster University, Massachusetts Institute of Technology. Study on AI-identified narrow-spectrum antibiotic (“enterololin”) targeting Enterobacteriaceae. Nature Microbiology. Full author list, volume, page range and DOI were not specified in the source material provided and have therefore been omitted rather than invented.
This article is a journalistic summary for informational purposes only. It does not constitute clinical advice or a recommendation to alter treatment decisions.